During the last session, ImmunityBio Inc (NASDAQ:IBRX)’s traded shares were 4.36 million, with the beta value of the company hitting 0.42. At the end of the trading day, the stock’s price was $2.78, reflecting an intraday gain of 1.46% or $0.04. The 52-week high for the IBRX share is $10.53, that puts it down -278.78 from that peak though still a striking 17.99% gain since the share price plummeted to a 52-week low of $2.28. The company’s market capitalization is $2.37B, and the average intraday trading volume over the past 10 days was 4.44 million shares, and the average trade volume was 5.98 million shares over the past three months.
ImmunityBio Inc (IBRX) received a consensus recommendation of Sell from analysts. That translates to a mean rating of 1.40. IBRX has a Sell rating from 1 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.14.
ImmunityBio Inc (NASDAQ:IBRX) trade information
ImmunityBio Inc (IBRX) registered a 1.46% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.46% in intraday trading to $2.78, hitting a weekly high. The stock’s 5-day price performance is 0.72%, and it has moved by -8.25% in 30 days. Based on these gigs, the overall price performance for the year is -54.20%. The short interest in ImmunityBio Inc (NASDAQ:IBRX) is 59.54 million shares and it means that shorts have 9.03 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 53.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, IBRX is trading at a discount of -115.83% off the target high and -115.83% off the low.
ImmunityBio Inc (IBRX) estimates and forecasts
In the rating firms’ projections, revenue will increase 613.74% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 17.5M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 23.5M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 40k and 1.05M respectively. In this case, analysts expect current quarter sales to grow by 43,644.38% and then jump by 2,144.10% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 2.39%. While earnings are projected to return 2.26% in 2025.
IBRX Dividends
ImmunityBio Inc is due to release its next quarterly earnings on 2025-Mar-02. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
ImmunityBio Inc insiders own 62.90% of total outstanding shares while institutional holders control 9.88%, with the float percentage being 26.63%. VANGUARD GROUP INC is the largest shareholder of the company, while 273.0 institutions own stock in it. As of 2024-06-30, the company held over 13.83 million shares (or 2.0558% of all shares), a total value of $87.42 million in shares.
The next largest institutional holding, with 11.42 million shares, is of BLACKROCK INC.’s that is approximately 1.6629% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $72.19 million.
Also, the Mutual Funds coming in first place with the largest holdings of ImmunityBio Inc (IBRX) shares are SPDR(R) S&P(R) Biotech ETF and Vanguard Total Stock Market Index Fund . Data provided on Feb 28, 2025 indicates that SPDR(R) S&P(R) Biotech ETF owns about 5.84 shares. This amounts to just over 0.68 percent of the company’s overall shares, with a $16.24 million market value. The same data shows that the other fund manager holds slightly less at 5.73, or about 0.67% of the stock, which is worth about $15.94 million.
